Thermo Fisher Q2 2026 Revenue Beats Estimates, EPS Up 5.6%
Thermo Fisher Scientific (TMO) reported Q2 2026 revenue of $11.99 billion, up 10.5% year-over-year and above analyst expectations. Non-GAAP earnings per share of $6.03 also beat consensus estimates by 5.6%.
Key Numbers
Life sciences company Thermo Fisher Scientific (NYSE:TMO) announced better-than-expected results for the second quarter of fiscal 2026. Revenue reached $11.99 billion, a 10.5% increase year-over-year, while non-GAAP earnings per share came in at $6.03, surpassing analyst consensus by 5.6%.
Key Financial Results
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Revenue | $11.99B | +10.5% |
| Non-GAAP EPS | $6.03 | +5.6% vs. estimates |
Highlights from the Release
The company did not provide additional details on growth drivers or segment performance in the press release. However, the revenue and earnings beat suggests strong demand for life sciences products and services.
Guidance
The company did not issue guidance for the next quarter or full fiscal 2026 in this announcement.
Stock Impact
TMO shares are expected to react positively to the strong results, as the revenue and earnings beat reinforces investor confidence in the company's performance.
What This Means for Investors
Thermo Fisher's strong Q2 results highlight continued demand for life sciences solutions, supporting a positive outlook. However, investors should watch for future guidance and industry trends to assess the sustainability of this growth.
Frequently Asked Questions
Found this useful? Share it